ÂÜÀòÂÒÂ×

Dr. Karim Benhadji serves as the Chief Medical Officer of GV20 Therapeutics. He has over 17 years of experience in biopharmaceutical oncology drug development.

He previously served as Senior Vice President, Head of Clinical Development and Operations at Taiho Oncology where he oversaw the development of early and late phase portfolio assets including regulatory fillings leading to the FDA approval of Lytgobi®.

Prior to joining Taiho Oncology, Dr. Benhadji spent over 13 years with Eli Lilly and Company in oncology development roles of increasing responsibility. He was most recently Vice President, Early Phase Oncology and oversaw several immuno-oncology programs.

Dr. Benhadji received his M.D. from the University of Oran. He has completed medical oncology fellowships in Universities of Oran and Paris 7 and holds a Master of Science in Pharmacology and Therapeutics in Oncology from the University of Paris 11.